- Presentation of interim data from phase 2 study of sotatercept in β-thalassemia patients – Acceleron announced on December 9, 2013, that its collaboration partner, Celgene, reported new interim data of sotatercept in patients with beta-thalassemia at the 55 th American Society of Hematology (ASH) Annual Meeting. Interim data presented from the ongoing phase 2 trial demonstrate dose dependent increases in hemoglobin across the three dose levels presented (0.1, 0.3 and 0.5 mg/kg) in non-transfusion dependent beta-thalassemia patients. Furthermore, increases in hemoglobin of at least 1-2 g/dL were observed in nearly all non-transfusion dependent patients at the 0.3 and 0.5 mg/kg dose levels.
- Early signs of activity from phase 2a study of sotatercept in end-stage renal disease patients – An interim analysis indicated sotatercept produces dose dependent increases in hemoglobin in end-stage renal disease patients on hemodialysis.
- Initiation of a phase 2b study of sotatercept in end-stage renal disease patients – Celgene initiated a phase 2b study of sotatercept for which Acceleron earned and received a $7.0 million milestone payment in December 2013.
- Initial interim data from phase 2 study of ACE-536 in β-thalassemia patients – Interim data from the first three dose levels in the ongoing phase 2 study demonstrated dose dependent increases in hemoglobin.
- Enrollment underway in the expansion cohort of the phase 2 trial of dalantercept in combination with axitinib in patients with renal cell carcinoma (RCC) – Acceleron completed enrollment in all dose escalation cohorts and is now enrolling patients in the expansion cohort in part 1 of this two part study.
- Dalantercept phase 1 study results published – The results from the phase 1 clinical trial of dalantercept in adults with solid tumors were published in January in Clinical Cancer Research showing that dalantercept exhibited a safety profile distinct from that of VEGF inhibitors and displayed multiple signs of antitumor activity.
- Acceleron added to the Russell 2000 ® index – On December 20, 2013, Acceleron was selected for addition to the Russell 2000 ®, Russell 3000 ® and Russell Global ® Indexes as part of Russell Investments’ quarterly addition of select recent initial public offering (IPO) companies.
- Follow-on offering – On January 28, 2014, Acceleron closed a follow-on offering of 2,760,000 shares of common stock. The aggregate net proceeds to the Company, after underwriting discounts and commissions and other estimated offering expenses, were approximately $129.0 million. The addition of the net proceeds of this financing to the 2013 year-end cash balance of $113.2 million is expected to provide the Company funding into the second half of 2017.
- Cash Position – Cash and cash equivalents as of December 31, 2013 were $113.2 million, compared to $39.6 million at December 31, 2012. The cash increase was primarily driven by total net proceeds of $96.8 million from, collectively, Acceleron’s initial public offering and the concurrent $10 million side-by-side private placement of common stock to Celgene. Acceleron expects that its cash and cash equivalents balance as of December 31, 2013, together with the net proceeds of $129.0 million raised in the follow-on public offering on January 28, 2014, will be sufficient to fund the Company’s operations into the second half of 2017.
- Revenue - Collaboration revenue was $11.5 million for the fourth quarter of 2013 and $57.2 million for the year ended December 31, 2013, compared to $4.0 million and $15.3 million for the comparable periods in 2012. The increase for the fourth quarter of 2013 compared to the comparable period in 2012 was primarily driven by the $7.0 million milestone from Celgene’s initiation of a phase 2b clinical trial of sotatercept in patients with end stage renal disease on hemodialysis earned and received in December 2013. The increase in 2013 collaboration revenue compared to 2012 was primarily driven by a $16.7 million increase in deferred revenue recognition caused by the termination of the Shire collaboration in the second quarter of 2013, a $10.0 million milestone earned in the first quarter of 2013 in connection with our Celgene collaboration for the first patient dosed in a phase 2 trial of ACE-536, a $7.0 million milestone earned in the fourth quarter of 2013 due to Celgene’s initiation of a phase 2b clinical trial of sotatercept in patients with end stage renal disease on hemodialysis, and an increase in cost-sharing revenue of $7.7 million.
- R&D Expenses – Research and development expenses were $10.2 million for the fourth quarter of 2013 and $36.1 million for the year ended December 31, 2013, compared to $9.7 million and $35.3 million for the comparable periods in 2012.
- G&A Expenses – General and administrative expenses were $4.8 million for the fourth quarter of 2013 and $14.2 million for the year ended December 31, 2013, compared to $2.5 million and $8.8 million for the comparable periods in 2012. The increase was largely driven by higher legal fees, as well as incremental expenses to support public company operations.
- Net Loss – Our net loss was $18.1 million for the fourth quarter of 2013 and $21.9 million for the year ended December 31, 2013, compared to a net loss of $10.4 million and $32.6 million for the comparable periods in 2012. The fourth quarter and year ended results were affected by the expenses associated with marking to market outstanding warrants to purchase of common stock. The expenses associated with the increase in the common warrant valuation of $14.2 million and $25.6 million for the three months and year ended December 31, 2013, respectively, were due to a higher December 31, 2013 closing stock price compared to the value of the Company’s stock in earlier periods.
- Initiation of the randomized, placebo-controlled stage of the dalantercept RCC study – Acceleron expects in late March or early April to begin part 2 of the RCC study which will be a randomized comparison of the selected doses of dalantercept in combination with axitinib versus axitinib. The primary endpoint of part 2 of the trial will be progression-free survival.
- Initiation of a phase 2a study of dalantercept in liver cancer – Acceleron expects in late first quarter or early second quarter 2014 to begin a phase 2a study of dalantercept in combination with sorafenib in patients with hepatocellular carcinoma.
- Presentation of interim data from phase 2a study of sotatercept in end-stage renal disease patients on hemodialysis – Interim data from this clinical trial will be presented at the National Kidney Foundation Spring Clinical Meeting in Las Vegas, Nevada in April 2014.
- Interim data from the dalantercept phase 2 clinical trials in RCC and head and neck cancer – Acceleron intends to announce these interim data in late May or early June at the annual meeting of the American Society of Clinical Oncology (ASCO).
- Interim data from the dose escalation stages of the sotatercept and ACE-536 clinical trials in β-thalassemia and MDS – Acceleron and Celgene intend to announce interim data in June at the annual congress of the European Hematology Association (EHA). For sotatercept and ACE-536 in β-thalassemia, we and Celgene expect to present additional interim data from non-transfusion dependent patients as well as data from transfusion dependent patients. In transfusion dependent β-thalassemia patients treated with ACE-536, preliminary data show a decrease in the frequency of red blood cell transfusions. For MDS patients treated with ACE-536, interim data indicates that there is a positive effect on hemoglobin levels in these patients, and we look forward to presenting data from both transfusion dependent and non-transfusion dependent MDS patients at EHA in June.
- Initiation of a phase 1 clinical trial with ACE-083 – Acceleron is conducting preclinical activities in preparation for the submission of an Investigational New Drug (IND) application for its clinical candidate ACE-083, a locally acting drug designed to increase muscle mass and strength. Acceleron aims to initiate a phase 1 clinical trial in the second half of 2014.
- Additional clinical studies for dalantercept – Acceleron is considering additional cancers such as colorectal and brain cancer to study in clinical trials that are expected to start in the second half of 2014.
About AcceleronAcceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases. The company is a leader in understanding the biology of the Transforming Growth Factor-Beta (TGF-β) protein superfamily, a large and diverse group of molecules that are key regulators in the growth and repair of tissues throughout the human body, and in targeting these pathways to develop important new medicines. Acceleron has built a highly productive R&D platform that has generated innovative clinical and preclinical protein therapeutic candidates with novel mechanisms of action. These protein therapeutic candidates have the potential to significantly improve clinical outcomes for patients with cancer and rare diseases. For more information, please visit www.acceleronpharma.com.
|ACCELERON PHARMA INC.|
|CONDENSED CONSOLIDATED BALANCE SHEET (UNAUDITED)|
|(Amounts in thousands)|
|December 31, 2013||December 31, 2012|
|Cash and cash equivalents||$||113,163||$||39,611|
|Notes payable, net of discount||16,868||20,193|
|Warrants to purchase common stock||30,753||5,229|
|Redeemable convertible preferred stock||—||268,610|
|Stockholders’ equity (deficit)||57,811||(290,973||)|
|Total liabilities, redeemable convertible preferred stock and Stockholders’|
|ACCELERON PHARMA INC.|
|CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)|
|(Amounts in thousands except per share data)|
|Three Months Ended December 31,||Year Ended December 31,|
|Costs and expenses:|
|Research and development||10,216||9,673||36,051||35,319|
|General and administrative||4,756||2,506||14,227||8,824|
|Total costs and expenses||14,972||12,179||50,278||44,143|
|(Loss) income from operations||(3,451||)||(8,194||)||6,952||(28,889||)|
|Other expense, net||(14,659||)||(2,185||)||(28,850||)||(3,693||)|
|Accretion of dividends, interest, redemption|
|value and issuance costs on redeemable|
|convertible preferred stock||—||(6,744||)||(19,870||)||(27,061||)|
|Gain on extinguishment of redeemable|
|convertible preferred stock||—||—||2,765||—|
|Net loss applicable to common stockholders –|
|basic and diluted||$||(18,110||)||$||( 17,123||)||$||(39,003||)||$||(59,643||)|
|Net loss per share applicable to common|
|Basic and diluted||$||(0.64||)||$||(7.10||)||$||(4.15||)||$||(24.84||)|
|Weighted average number of common shares|
|used in computing net loss per share|
|applicable to common stockholders:|
|Basic and diluted||28,123||2,416||9,407||2,401|